摘要
二肽基肽酶-4（DPP-4）抑制剂是一种新型的2型糖尿病治疗药物，通过抑制DPP-4，升高包括胰升糖素样肽-1（GLP-1）在内的多种内源性肠促胰岛素，产生降糖作用。除升高GLP-1外，DPP4还能广泛裂解炎症、免疫和血管功能调节中涉及的多种细胞因子、趋化因子和神经肽。已经证实GLP-1具有心血管系统的保护作用。由于上述非靶机制的存在，DPP-4抑制剂还具有独立于GLP-1之外的心血管保护作用，其中对内皮祖细胞、炎症过程、缺血反应和血脂的调节是其主要作用靶点。
Dipeptydil-peptidase-4 （DPP-4） inhibitors are designed as oral anti-hyperglycemic drugs for the treatment of type 2 diabetes owing to their effects on the incretin system through sparing incretin hormones including glucagon-like peptide-1 （ GLP-1 ） from rapid degradation by DPP-4. It has been shown that GLP-1 signaling may exert beneficial effects on cardiovascular system. In addition to GLP-1, DPP-4 physiologically cleaves cytokines, chemokines, and neuropeptides involved in inflammation, immunity, and vascular function. It means that DPP-4 inhibitors hold promise for cardiovascular protection independent of GLP-1. And its modulation of endothelial progenitor cells, inflammatory pathway, ischemic response, and lipid metabolism emerges as the major cardiovascular target of DPP-4 inhibitors.
出处
《中华内分泌代谢杂志》
CAS
CSCD
北大核心
2014年第3期258-260,共3页
Chinese Journal of Endocrinology and Metabolism
基金
国家青年自然科学基金（81000321）
